Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SOD1 | P00441 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7881607 | 0.93 | CYP1A2 (0.42) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL8142070 | 0.86 | CA2 (0.32) | CA1CA2CA9 | |
| SCHEMBL95869 | 0.74 | SOS1 (0.39) | CA1CA2CA9MAOBDAO | |
| SCHEMBL7003904 | 0.74 | CA1 (0.43) | CA1CA2CA9CES2CES1 | |
| SCHEMBL96667 | 0.74 | CA1 (0.58) | CA1CA2CA9CYP2A6CYP3A4 | |
| SCHEMBL95901 | 0.74 | ACHE (0.48) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL4867495 | 0.74 | MEN1 (0.50) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL2088495 | 0.74 | TSHR (0.42) | CYP3A4MAPTCYP2C19SOD1ALDH1A1 | |
| SCHEMBL97751 | 0.74 | CA2 (0.43) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL1417001 | 0.74 | LMNA (0.42) | MEN1KMT2ACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2636669-B1 | PYRAZOLE AMIDE COMPOUND AND USE THEREOF AS FUNGICIDE | SINOCHEM CORP (CN) | 2015-10-21 | — | — | EP | claimed |
| CN-104177340-A | Novel quinazoline (sulfur) ketone compound and application | SINOCHEM CORP | 2014-12-03 | — | — | CN | claimed |
| EP-2636669-A1 | PYRAZOLE AMIDE COMPOUND AND USE THEREOF | Sinochem Corporation (CN) | 2013-09-11 | — | — | EP | claimed |
| US-20130225585-A1 | PYRAZOLE AMIDE COMPOUNDS AND USES THEREOF | SHENYANG RESEARCH INSTITUTE OF CHEMICAL INDUSTRY CO., LTD. (CN) | 2013-08-29 | — | — | US | claimed |
| WO-2010128516-A2 | PROCESS FOR THE PREPARATION OF FLIBANSERIN INVOLVING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2010-11-11 | — | — | WO | claimed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | claimed |
| CN-100343260-C | Cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2007-10-17 | — | — | CN | claimed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | claimed |
| EP-1134222-B1 | IMIDAZO[4,5-b]PYRIDINIUMMETHYL-CONTAINING CEPHEM COMPOUNDS HAVING BROAD ANTIBACTERIAL SPECTRUM | SHIONOGI & CO (JP) | 2005-04-13 | — | — | EP | claimed |
| EP-1506175-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | claimed |
| US-5506362-A | Process for the preparation of an α-amino acid amide | SOLVAY (SOCIETE ANONYME) (BE) | 1996-04-09 | — | — | US | claimed |
| US-5234930-A | Treating psychological, cardiovascular, urogenital and respiratory disorders; diabetes, asthmas, sudden infant death syndrome | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | claimed |
| EP-0160252-B1 | Antibacterial compounds | Takeda Chemical Industries, Ltd. (JP) | 1992-08-26 | — | — | EP | claimed |
| EP-0354297-B1 | THIADIAZINES, PROCESS FOR PRODUCTION THEREOF, AND INSECTICIDAL AND ACARICIDAL AGENTS COMPRISING THE THIADIAZINES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-08-05 | — | — | EP | claimed |
| US-4788185-A | Cephalosporin compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-11-29 | — | — | US | claimed |
| US-4361514-A | Carbon analogs of penicillin | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1982-11-30 | — | — | US | claimed |
| US-4282149-A | Carbon and oxygen analogs of penicillin | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1981-08-04 | — | — | US | claimed |
| US-4076717-A | Derivatives of 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid | G. D. SEARLE & CO. (US) | 1978-02-28 | — | — | US | claimed |
| US-3991042-A | Basic azo dyestuffs containing a benzthiazole and a tetrahydroquinoline nucleus | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-09 | — | — | US | claimed |
| US-3948877-A | POLYACRYLONITRILE, ACID MODIFIED POLYESTERS OR POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225585-A1 | PYRAZOLE AMIDE COMPOUNDS AND USES THEREOF | BROX, OAT, CAT | MEN1 2649/4885KMT2A 2422/4885CA1 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.